Status message

Active context: kki_bg_colors_yellow

D1050302: A 104-week, flexible-dose, open-label, multicenter, extension study to evaluate the long-term safety and effectiveness of Lurasidone in pediatric subjects with schizophrenia and subjects with irritability associated with autistic disorder

Principal Investigator:

This open-label extension study is designed to evaluate the safety, tolerability, and effectiveness of lurasidone for the treatment irritability in individuals with autistic disorder. As an extension of NA_00089697, this 104-week study will provide an adequate time frame to evaluate the long-term effects of lurasidone in this patient population.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.